Download PDF
Thromb Haemost 1981; 46(04): 734-739
DOI: 10.1055/s-0038-1653464
Original Article
Schattauer GmbH Stuttgart

The Lupus Inhibitor: A Study of Its Heterogeneity

M C Coots
The Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, U. S.A.
,
M A Miller
The Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, U. S.A.
,
H I Glueck
The Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, U. S.A.
› Author Affiliations
Further Information

Publication History

Received 30 June 1981

Accepted 14 October 1981

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The plasmas of six patients with prolonged activated partial thromboplastin times were studied in detail. In five of the six, the Russell’s viper venom and prothrombin times were likewise prolonged. Five of the patients had documented systemic lupus erythematosus; one lacked the necessary criteria for this diagnosis. On quantitation, factor XI was decreased in all six; factors X and XII were diminished in five of the six. When tested for inhibitory activity, plasma from each of the patients prolonged the celite eluate inhibition test for factor XII and/or XI inhibition. In the formation of the Xa-V-phospholipid-Ca2+ complex (prothrombinase), factors X and Xa were inhibited to a greater degree than factor V or the phospholipid. Finally, each plasma was isofocused, the inhibitory fractions were identified and the clotting factor specificity of each inhibitory peak was determined.Fractions inhibitory against factors XI and XII isofocused with the IgG in each patient’s plasma. Based on the data presented from these six patients, the “lupus inhibitor” is in fact a heterogeneous collection of inhibitors directed against factors XII, XI and X rather than a homogeneous entity.

Keywords

Lupus inhibitor - Isofocusing - Factor X inhibitor - Factor XI inhibitor - Factor XII inhibitor
 

  • References

  • 1 Frick PG. Acquired circulating anticoagulant in systemic“collagen disease”. Autoimmune thromboplastin deficiency Blood 1955; 10: 691-706
    CrossrefPubMedGoogle Scholar
  • 2 Schieider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
    PubMedGoogle Scholar
  • 3 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. In: Progress in Hemostasis and Thrombosis (T Spaet). Vol 1 pp 75-95 1972. Grune and Stratton; New York, N. Y:
    Google Scholar
  • 4 Lechner K. A new type of coagulation inhibitor. Thrombos Diathes Haemorrh 1969; 21: 482-499
    PubMedGoogle Scholar
  • 5 Thiagarajan P, Shapiro SS. Lupus anticoagulants are antibodies reactive against phospholipids. Circulation (Abstracts) 1980; Part II 62: 279 Abstract Number 1069
    PubMedGoogle Scholar
  • 6 Lee SL, Sanders M. A disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest 1955; 34: 1814-1822
    CrossrefPubMedGoogle Scholar
  • 7 Laurell A, Nilsson IM. Hyperglobulinemia, circulating anticoagulant and biologic false positive Wasserman reaction. J Lab Clin Med 1957; 49: 694-707
    PubMedGoogle Scholar
  • 8 Bowie EW, Thompson JH, Cascuzzi PA, Owen CA. Thrombosis in SLE despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430
    PubMedGoogle Scholar
  • 9 Mayer G, Mayer S, Waitz R. Anticoagulant circulant associé à une thrombopénie. Hémostase 1967; 5: 21-36
    PubMedGoogle Scholar
  • 10 Veltkamp H, Kerkhoven P, Loeliger EA. Circulating anticoagulant in disseminated lupus erythematosus: Proposed mode of action. Haemostasis 1974; 2: 25
    PubMedGoogle Scholar
  • 11 Lechner K. Acquired inhibitors in non-hemophilic patients. Haemostasis 1974; 3: 65-93
    PubMedGoogle Scholar
  • 12 Gobbi F, Stefanini M. Circulating anti-AHG anticoagulant in a patient with lupus erythematosus disseminatus. Effect of a cephalin complex in vivo Acta haematol 1962; 28: 155-162
    CrossrefPubMedGoogle Scholar
  • 13 Regan MG, Lackner H, Karpatkin S. Platelet function and coagulation profile in lupus erythematosus. Ann Int Med 1974; 81: 462-468
    CrossrefPubMedGoogle Scholar
  • 14 Robboy SJ, Lewis EJ, Schur PH, Colman RW. Circulating anticoagulants and clinical response to factor VIII concentrates. Am J Med 1970; 49: 742
    CrossrefPubMedGoogle Scholar
  • 15 Okpara RA, Carabello JA, Day JH. Spurious prolongation of the activated partial thromboplastin time. Thromb Haemostas 1977; 38: 900-908
    PubMedGoogle Scholar
  • 16 Castro O, Färber LR, Clyne LP. Circulating anticoagulant against factors IX and XI in systemic lupus erythematosus. Ann Int Med 1972; 77: 543-548
    CrossrefPubMedGoogle Scholar
  • 17 Bonnin JA, Cohen AK, Hicks ND. Coagulation defects in a case of systemic lupus erythematosus with thrombocytopenia. Br J Haematol 1956; 2: 168-179
    CrossrefPubMedGoogle Scholar
  • 18 Margolis A JR, Jackson DP, Ratnoff OD. Circulating anticoagulants: A study of 40 cases and review of the literature. Medicine 1961; 40: 145-202
    CrossrefPubMedGoogle Scholar
  • 19 Aberg H, Nilsson IM. Recurrent thrombosis in a young man with a circulating anticoagulant against IX and XI in SLE. Acta med Scand 1972; 192: 419-425
    PubMedGoogle Scholar
  • 20 Sánchez-Medal L, Lisker R, López ET. Unusual circulating anticoagulant in a patient with systemic lupus erythematosus. Acta haematol 1963; 29: 117-122
    CrossrefPubMedGoogle Scholar
  • 21 Largo R, Sigg P, Felten Avon, Straub PW. Erworbener Factor IX–Hemmkörper bei einem nicht-hämophilen Patienten mit Autoimmun-krankheit. Schweiz med Wschr 1972; 102: 1612-1613
    PubMedGoogle Scholar
  • 22 Breckenridge RJ, Ratnoff OD. Studies on the site of action of a circulating anticoagulant in disseminated lupus erythematosus. Am J Med 1963; 35: 813-819
    CrossrefPubMedGoogle Scholar
  • 23 Leone G, Accorra F, Boni P. Circulating anticoagulant against factor XI and thrombocytopenia with platelet aggregation inhibition in systemic lupus erythematosus. Acta haematol 1977; 58: 240-245
    CrossrefPubMedGoogle Scholar
  • 24 Krieger H, Leddy JP, Breckenridge RT. Studies on a circulating anticoagulant in systemic lupus.. Evidence of inhibition of the function of activated plasma thromboplastin antecedent (factor XIa) Blood 1975; 46: 189-197
    PubMedGoogle Scholar
  • 25 Cronberg S, Nilsson IM. Circulating anticoagulant against factors XI and XII together with spontaneous platelet aggregation. Scand J Haematol 1973; 10: 309-314
    PubMedGoogle Scholar
  • 26 Di Sabatino CA, Clyne LP, Malawista SE. A circulating anticoagulant directed against factor XIain systemic lupus erythematosus. Arthritis Rheum 1979; 22: 1135-1138
    CrossrefPubMedGoogle Scholar
  • 27 Gandolfo GM, Afeltra A, Amoroso A, Biancollella F, Ferri GM. Circulating anticoagulant against factor XII and platelet antibodies in systemic lupus erythematosus. Acta Haematol 1977; 57: 135-142
    CrossrefPubMedGoogle Scholar
  • 28 Rodman GP. (ed) Preliminary criteria for the classification of systemiclupus erythematosus. In: Primer on the Rheumatic Diseases, Edition 7 American Rheumatism Association Section of the Arthritis Foundation 1973; 139
    PubMedGoogle Scholar
  • 29 Coots MC, Muhleman AF, Glueck HI. Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 1978; 4: 193-206
    CrossrefPubMedGoogle Scholar
  • 30 Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145: 495-503
    CrossrefPubMedGoogle Scholar
  • 31 Stander RW, Flessa HC, Glueck HI, Kisker CT. Changes in maternal coagulation factors after intra-amniotic injection of hypertonic saline. Obstet Gynecol 1971; 37: 660-666
    PubMedGoogle Scholar
  • 32 Denson K WE, Borrett R, Biggs R. The specific assay of prothrombin using Taipan snake venom. Br J Haematol 1971; 21: 219-226
    CrossrefPubMedGoogle Scholar
  • 33 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-320
    PubMedGoogle Scholar
  • 34 Mitchell GA, Hudson P, Huseby RM, Pochron SP, Garguilo A. Fluorescent substrate assay for antithrombin HI. Thromb Res 1978; 12: 219-225
    CrossrefPubMedGoogle Scholar
  • 35 Bnnkhous KM, Graham JE, Cooper HA, Allain JP, Wagner RH. Assay of von Willebrand factor in von Willebrand’s disease and hemophilia: Use of a macroscopic platelet aggregation test. Thromb Res 1975; 6: 267-272
    CrossrefPubMedGoogle Scholar
  • 36 Nossel HL. The Contact Phase of Blood Coagulation. F. A. Davis Company; Philadelphia: 1964: 45
    Google Scholar
  • 37 Waaler BA. Contact activation in the intrinsic blood clotting system. Scand J Clin Lab Invest 1959; 11 Suppl (Suppl. 37) 56
    PubMedGoogle Scholar
  • 38 Bell WN, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 1954; 174: 880-881
    CrossrefPubMedGoogle Scholar
  • 39 Malhotra OP, Carter JR. A simple method for preparing substrate for factor X assay. Fed Proc 1966; 25: 256
    PubMedGoogle Scholar
  • 40 Rodman Jr NF, Barrow EM, Graham JB. Diagnosis and control of hemophilloid states with the partial thromboplastin time (PTT) test. Am J Clin Pathol 1958; 29: 525-538
    CrossrefPubMedGoogle Scholar
  • 41 Glueck HI, Wachman J. A TAMe micromethod for the measurement of esterase prothrombin. Am J Clin Pathol 1970; 54: 239-248
    CrossrefPubMedGoogle Scholar
  • 42 Firkin BG, Booth P, Hendrix L, Howard MA. Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant. Am J Hematol 1978; 5: 81-92
    CrossrefPubMedGoogle Scholar
  • 43 Schiffman S, Theodor I, Rapaport SI. Separation from Russell’s viper venom of one fraction reacting with factor X and another reacting with factor V. Biochemistry 1969; 8: 1397-1405
    CrossrefPubMedGoogle Scholar
  • 44 Lindquist PA, Fujikawa K, Davie EW. Activation of bovine IX by a protease from Russell’s viper venom. Fed Proc 1976; 35: 1353
    PubMedGoogle Scholar
  • 45 Seligsohn U, Østerud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems: Roles of activated factor IX, kallikrein and activated factor XII. J Clin Invest 1979; 64: 1056-1065
    CrossrefPubMedGoogle Scholar
  • 46 Fantl P, Nance MH. An acquired haemorrhagic disease in a female due to an inhibitor of blood coagulation. Med J Aust 1946; 1: 125-128
    PubMedGoogle Scholar